Gold Falls Over 1%; HilleVax Shares Plunge
- U.S. Stock Market: Nasdaq Composite moved higher, Dow down 0.12%, NASDAQ up 0.27%, S&P 500 gained 0.09%.
- Top Headline: Eli Lilly to acquire Morphic Holding Inc for $3.2 billion.
- Equities Trading UP: Shares of Morphic Holding, Myomo, and SRIVARU Holding increased significantly.
- Equities Trading DOWN: HilleVax, Wetouch Technology, and Inventiva S.A. saw declines in their stock prices.
- Commodities and Global Markets: Oil and gold prices fell, European shares closed lower, Asian markets also declined.
Trade with 70% Backtested Accuracy
Analyst Views on MYO
About MYO
About the author
Myomo, Inc. Reports Strong Q4 2025 Earnings with Strategic Focus
- Significant Revenue Growth: Myomo reported $11.4 million in revenue for Q4 2025, reflecting a 26% increase over 2024, with full-year revenue reaching $40.9 million, showcasing the company's success in direct-to-patient marketing and recurring revenue sources.
- Record Orders: The company received 241 MyoPro orders in the quarter, a 5% increase from Q3, indicating not only rising product demand but also successful penetration in the O&P channel and international markets.
- Strategic Partnership Expansion: The new multistate agreement with Elevance Health covers 45 million lives, marking a significant advancement in payer contracts that is expected to support future revenue growth.
- Cautious Future Outlook: Management expects Q1 2026 revenue in the range of $9 million to $9.5 million and sets a full-year target of $43 million to $46 million, reflecting a cautious stance towards market uncertainties while planning to improve gross margins through controlled operating expenses.
Myomo Q4 Earnings Report Analysis
- Disappointing Earnings: Myomo reported a Q4 non-GAAP EPS of -$0.37, missing expectations by $0.28, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Slight Revenue Decline: The company's Q4 revenue of $11.4 million represents a 5.6% year-over-year decline, although it beat expectations by $1 million, the revenue drop reflects weak market demand, potentially affecting future growth prospects.
- Deteriorating Adjusted EBITDA: The adjusted EBITDA for Q4 2025 was -$1.9 million, a significant decline from $0.2 million in Q4 2024, with a full-year adjusted EBITDA of -$11.5 million compared to -$5.1 million in 2024, indicating a decrease in operational efficiency.
- Tight Cash Flow Situation: As of December 31, 2025, the company had $18.4 million in cash and cash equivalents, with Q4 operating cash flow at -$1.1 million, a sharp decline from $3.4 million generated in Q4 2024, highlighting liquidity pressures faced by the company.
Myomo to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Myomo is set to release its Q4 earnings on March 9 after market close, with a consensus EPS estimate of -$0.09, reflecting an alarming 800% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: Analysts predict Myomo's Q4 revenue will be $10.4 million, down 13.8% year-over-year, highlighting the company's struggles in a competitive market and sluggish sales growth.
- Historical Performance Review: Over the past year, Myomo has beaten EPS estimates 75% of the time and revenue estimates 100% of the time, demonstrating stability in profitability and revenue despite current downward pressures.
- Market Reaction Anticipation: Given the current earnings expectations and historical performance, investors may adopt a cautious stance towards the upcoming earnings report, particularly as the company faces simultaneous declines in both profitability and revenue.
Myomo, Inc. Activist Investor Pushes Governance Changes
- Governance Change Signal: Horton Capital Partners recently filed a Schedule 13D for Myomo, Inc., indicating it has crossed the 5% ownership threshold and aims to push for governance changes by eliminating the classified board structure for annual elections, which could enhance management accountability and potentially shift the company's strategic direction.
- Market Potential: Myomo focuses on wearable robotic devices primarily serving patients with neuromuscular disorders like stroke-related paralysis; despite uneven revenue growth, its technology addresses a growing clinical need, and governance changes may attract more investor interest.
- Early Stage Activism: Lakeland Industries has seen an 8.38% stake acquired by Global Value Investment Corporation, signaling intent to engage in governance and strategic discussions, which could drive value enhancement in the protective apparel market.
- Microcap Activism: Chicago Rivet & Machine Co. has 6.45% of its shares acquired by Galloway and others, indicating belief in the company's undervaluation, which may prompt management to reassess strategy and alter the company's future trajectory.
Myomo reaffirms its revenue goal of $40M–$42M for 2025, fueled by growth in the O&P channel and MyoConnect.
Management Performance: Myomo, Inc. reported a strong Q3 2025 with revenues of $10.1 million, driven by record international sales and increased authorizations, while also announcing a strategic shift in advertising focus and the hiring of a new marketing head.
Financial Overview: The company experienced a 10% year-over-year revenue increase, with significant growth in the O&P channel and international markets, although gross margins declined due to rising costs. Operating losses were reported at $3.5 million.
Future Outlook: Myomo reiterated its full-year revenue guidance of $40 million to $42 million for 2025, emphasizing plans to diversify revenue streams and improve operating leverage while managing cash burn in 2026.
Analyst Sentiment: Analysts expressed constructive curiosity regarding operational details and strategic shifts, while management maintained a confident tone, highlighting progress in pipeline growth and ongoing efforts to address challenges in payer authorizations.
Myomo's Earnings Forecast for Q3 2025
Earnings Announcement: Myomo (MYO) is set to release its Q3 earnings results on November 10th, after market close.
EPS and Revenue Estimates: The consensus EPS estimate is -$0.11, reflecting a 266.7% year-over-year decline, while the revenue estimate is $9.44 million, indicating a 2.5% year-over-year increase.
Revisions Overview: Over the past three months, there have been no upward revisions for EPS or revenue estimates, but five downward revisions for each.
Future Growth Target: Myomo has revised its revenue growth target for 2025 to between 23% and 29%, citing improvements in lead quality and pipeline conversion.
Myomo, Inc. Reports Strong Q4 2025 Earnings with Strategic Focus
- Significant Revenue Growth: Myomo reported $11.4 million in revenue for Q4 2025, reflecting a 26% increase over 2024, with full-year revenue reaching $40.9 million, showcasing the company's success in direct-to-patient marketing and recurring revenue sources.
- Record Orders: The company received 241 MyoPro orders in the quarter, a 5% increase from Q3, indicating not only rising product demand but also successful penetration in the O&P channel and international markets.
- Strategic Partnership Expansion: The new multistate agreement with Elevance Health covers 45 million lives, marking a significant advancement in payer contracts that is expected to support future revenue growth.
- Cautious Future Outlook: Management expects Q1 2026 revenue in the range of $9 million to $9.5 million and sets a full-year target of $43 million to $46 million, reflecting a cautious stance towards market uncertainties while planning to improve gross margins through controlled operating expenses.
Myomo Q4 Earnings Report Analysis
- Disappointing Earnings: Myomo reported a Q4 non-GAAP EPS of -$0.37, missing expectations by $0.28, indicating ongoing challenges in profitability that could negatively impact investor confidence.
- Slight Revenue Decline: The company's Q4 revenue of $11.4 million represents a 5.6% year-over-year decline, although it beat expectations by $1 million, the revenue drop reflects weak market demand, potentially affecting future growth prospects.
- Deteriorating Adjusted EBITDA: The adjusted EBITDA for Q4 2025 was -$1.9 million, a significant decline from $0.2 million in Q4 2024, with a full-year adjusted EBITDA of -$11.5 million compared to -$5.1 million in 2024, indicating a decrease in operational efficiency.
- Tight Cash Flow Situation: As of December 31, 2025, the company had $18.4 million in cash and cash equivalents, with Q4 operating cash flow at -$1.1 million, a sharp decline from $3.4 million generated in Q4 2024, highlighting liquidity pressures faced by the company.
Myomo to Announce Q4 Earnings on March 9
- Earnings Announcement Schedule: Myomo is set to release its Q4 earnings on March 9 after market close, with a consensus EPS estimate of -$0.09, reflecting an alarming 800% year-over-year decline, indicating significant profitability challenges for the company.
- Revenue Decline Forecast: Analysts predict Myomo's Q4 revenue will be $10.4 million, down 13.8% year-over-year, highlighting the company's struggles in a competitive market and sluggish sales growth.
- Historical Performance Review: Over the past year, Myomo has beaten EPS estimates 75% of the time and revenue estimates 100% of the time, demonstrating stability in profitability and revenue despite current downward pressures.
- Market Reaction Anticipation: Given the current earnings expectations and historical performance, investors may adopt a cautious stance towards the upcoming earnings report, particularly as the company faces simultaneous declines in both profitability and revenue.
Myomo, Inc. Activist Investor Pushes Governance Changes
- Governance Change Signal: Horton Capital Partners recently filed a Schedule 13D for Myomo, Inc., indicating it has crossed the 5% ownership threshold and aims to push for governance changes by eliminating the classified board structure for annual elections, which could enhance management accountability and potentially shift the company's strategic direction.
- Market Potential: Myomo focuses on wearable robotic devices primarily serving patients with neuromuscular disorders like stroke-related paralysis; despite uneven revenue growth, its technology addresses a growing clinical need, and governance changes may attract more investor interest.
- Early Stage Activism: Lakeland Industries has seen an 8.38% stake acquired by Global Value Investment Corporation, signaling intent to engage in governance and strategic discussions, which could drive value enhancement in the protective apparel market.
- Microcap Activism: Chicago Rivet & Machine Co. has 6.45% of its shares acquired by Galloway and others, indicating belief in the company's undervaluation, which may prompt management to reassess strategy and alter the company's future trajectory.
Myomo reaffirms its revenue goal of $40M–$42M for 2025, fueled by growth in the O&P channel and MyoConnect.
Management Performance: Myomo, Inc. reported a strong Q3 2025 with revenues of $10.1 million, driven by record international sales and increased authorizations, while also announcing a strategic shift in advertising focus and the hiring of a new marketing head.
Financial Overview: The company experienced a 10% year-over-year revenue increase, with significant growth in the O&P channel and international markets, although gross margins declined due to rising costs. Operating losses were reported at $3.5 million.
Future Outlook: Myomo reiterated its full-year revenue guidance of $40 million to $42 million for 2025, emphasizing plans to diversify revenue streams and improve operating leverage while managing cash burn in 2026.
Analyst Sentiment: Analysts expressed constructive curiosity regarding operational details and strategic shifts, while management maintained a confident tone, highlighting progress in pipeline growth and ongoing efforts to address challenges in payer authorizations.
Myomo's Earnings Forecast for Q3 2025
Earnings Announcement: Myomo (MYO) is set to release its Q3 earnings results on November 10th, after market close.
EPS and Revenue Estimates: The consensus EPS estimate is -$0.11, reflecting a 266.7% year-over-year decline, while the revenue estimate is $9.44 million, indicating a 2.5% year-over-year increase.
Revisions Overview: Over the past three months, there have been no upward revisions for EPS or revenue estimates, but five downward revisions for each.
Future Growth Target: Myomo has revised its revenue growth target for 2025 to between 23% and 29%, citing improvements in lead quality and pipeline conversion.
